A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: Eribulin mesylate injection、Pertuzumab、Trastuzumab
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University